



**NMS Labs**

**CONFIDENTIAL**

200 Welsh Road, Horsham, PA 19044-2208  
Phone: (215) 657-4900 Fax: (215) 657-2972  
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

**Demo Report**

**Report Issued** 03/30/2020 13:29  
**Last Report Issued** 07/02/2015 12:00

**88888**  
Clinical Example Report  
Attn: Example Reports  
200 Welsh Road  
Horsham, PA 19044

**Patient Name** 4329B-POS  
**Patient ID** 4329B-POS  
**Chain** 15001604  
**Age** Not Given **DOB** Not Given  
**Gender** Not Given  
**Workorder** 15001604  
**Received** 07/02/2015 07:45

**Sample ID** 15001604-001  
**Matrix** Blood  
**Patient Name** 4329B-POS  
**Patient ID** 4329B-POS  
**Container Type** Clear vial

**Collect Dt/Tm** Not Given  
**Source** Not Given

**Approx Vol/Weight** Not Given

**Receipt Notes** None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
-----------------------	--------	-------	-----------------	-------

**4329B Terazosin, Blood**

Analysis by High Performance Liquid Chromatography/  
Tandem Mass Spectrometry (LC-MS/MS)

Terazosin	50	ng/mL	2.0	
Synonym(s): Hytrin®; Zayasel®				
One hour peak plasma levels after multiple-dose oral administration given twice daily for 4 consecutive days: 12 ng/mL (0.5 mg), 31 ng/mL (1.0 mg) and 42 ng/mL (2.0 mg).				

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.